Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. US: Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). One patient in the 10 mg dose level discontinued after Week 12 due to recurrent uveitis flare- up. Asian cohort: excludes one patient with a significant epiretinal membrane at baseline (exclusion criterion). One patient discontinued after Week 12 due to a spinal fracture. Results are site reported CST values. U.S. Asia KSI-101 consistently achieved dryness (CST 250-325 μm) after a single injection, with sustained dryness observed during follow-up 200 300 400 500 600 0 4 8 12 16 20 24 Mean CST (μm) Weeks U.S. 2.5 mg U.S. 5 mg U.S. 10 mg Asia Pooled 2.5 mg 13 12 13 13 13 13 13 12 5 mg 13 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 12 Pooled 12 12 12 12 12 11 11 11 Dryness (CST 250 – 325) Observed OCT CST Sample Size Rapid improvement demonstrated within 1 week 1 59